Related Experiment Video

Updated: Sep 23, 2025

Intracerebroventricular Treatment with Resiniferatoxin and Pain Tests in Mice
06:04

Intracerebroventricular Treatment with Resiniferatoxin and Pain Tests in Mice

Published on: September 2, 2020

8.3K

Systemic, Intrathecal, and Intracerebroventricular Antihyperalgesic Effects of the Calcium Channel Blocker CTK

Juliana Cavalli1, Pollyana Mendonça de Assis2, Elaine Cristina Dalazen Gonçalves1,3

  • 1Laboratório de Autoimunidade E Imunofarmacologia, Departamento de Ciências da Saúde, Universidade Federal de Santa Catarina, Campus Araranguá, Araranguá, SC, 88906-072, Brazil.

Molecular Neurobiology
|May 15, 2022
PubMed

Insights

A novel spider toxin peptide, CTK 01512-2, effectively reduces pain in chronic pain models. This N-type voltage-gated calcium channel blocker shows promise for systemic pain relief and supports glial cell health.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Toxicology

Background:

  • Persistent pain conditions like chronic post-ischemia pain (CPIP) and paclitaxel-induced peripheral neuropathy represent significant unmet medical needs.
  • Voltage-gated calcium channels (VGCCs) are critical in pain signaling pathways.
  • The Phoneutria nigriventer spider venom contains peptides with potent analgesic properties.

Purpose of the Study:

  • To evaluate the efficacy of CTK 01512-2, a recombinant Phα1β peptide, in preclinical models of persistent pain.
  • To investigate the effects of CTK 01512-2 on mechanical hypersensitivity and thermal allodynia via systemic, intrathecal, and intracerebroventricular administration.
  • To assess the impact of CTK 01512-2 on glial cell viability.

Main Methods:

  • Utilized chronic post-ischemia pain (CPIP) and paclitaxel-induced peripheral neuropathy models in rodents.
  • Administered CTK 01512-2 systemically, intrathecally, and intracerebroventricularly.
  • Assessed pain behaviors (mechanical hypersensitivity, thermal allodynia) and glial cell viability using MTT assay.

Main Results:

  • Intrathecal and systemic CTK 01512-2 significantly reduced mechanical hypersensitivity in the CPIP model.
  • Intrathecal CTK 01512-2 alleviated thermal allodynia in the CPIP model.
  • Intracerebroventricular CTK 01512-2 demonstrated antihyperalgesic and antiallodynic effects in paclitaxel-induced neuropathy.
  • CTK 01512-2 enhanced glial cell viability in the MTT assay.

Conclusions:

  • CTK 01512-2 exhibits significant therapeutic potential for treating persistent pain conditions.
  • Systemic administration of CTK 01512-2 is a viable route for pain management.
  • CTK 01512-2's positive effect on glial cell viability suggests a novel mechanism for chronic pain management.
Keywords:
CTK 01512–2Drug administration routeHyperalgesiaIntracerebroventricularNeuropathic painPeptide toxinsPhα1βω-conotoxin MVIIA

More Related Videos

Development of Recombinant Proteins to Treat Chronic Pain10:37

Development of Recombinant Proteins to Treat Chronic Pain

Published on: April 11, 2018

9.6K
Establishing a Mouse Model of a Pure Small Fiber Neuropathy with the Ultrapotent Agonist of Transient Receptor Potential Vanilloid Type 109:39

Establishing a Mouse Model of a Pure Small Fiber Neuropathy with the Ultrapotent Agonist of Transient Receptor Potential Vanilloid Type 1

Published on: February 13, 2018

9.7K

Related Concept Videos

Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
835
Local Anesthetics: Adverse Effects01:12

Local Anesthetics: Adverse Effects

While local anesthetics are generally safe and well-tolerated, they can occasionally cause adverse effects that vary in severity. Local anesthetics can induce toxicity at two distinct levels. They can either produce local effects through direct contact with the neural elements or be absorbed into the bloodstream from the injection site, leading to systemic effects.
Once absorbed into the systemic circulation, local anesthetics can affect the organs that depend on the functioning of sodium...
509
Local Anesthetics: Clinical Application as Spinal Anesthesia01:11

Local Anesthetics: Clinical Application as Spinal Anesthesia

Spinal anesthetics are given during lower abdomen and limb surgeries to block sensory and motor neurons. They are administered in the mid to low lumbar regions, primarily acting on the cauda equina's nerve roots. The blockade level depends on the local anesthetic (LA) concentration. Usually, low LA concentrations are sufficient to block sensory fibers, while only high LA concentrations block motor fibers. Other factors like injection volume and speed, the patient's posture, and the drug...
832
Local Anesthetics: Clinical Application as Epidural Anesthesia01:29

Local Anesthetics: Clinical Application as Epidural Anesthesia

Epidural anesthetics are administered in the fat-filled epidural space, the outermost part of the spinal canal. This technique is commonly employed for pain management and anesthesia during lower abdomen and pelvis surgeries or labor and delivery.
Since epidural anesthetics can be infused through an epidural catheter, all types of drugs, including short-acting ones, can be administered. Chloroprocaine and lidocaine are examples of short and long-duration anesthetics, respectively. Bupivacaine...
510